NIMIUM Therapeutics and Paraza Pharma form partnership to develop new medicines to treat cardiometabolic diseases (CMDs), obesity and type 2 diabetes

MONTREAL, July 20, 2021 /PRNewswire/ -- NIMIUM Therapeutics (www.nimium.ca), a Montreal-based biotech, has formed a partnership with Paraza Pharma (www.parazapharma.com) to develop a new treatment for cardiometabolic diseases (CMDs). The treatment aims to prevent and reverse the adverse effects of excess sugar and caloric intake and to promote healthier aging. The partnership will focus on the early-stage development of glycerol-3-phosphate phosphatase (G3PP) activators.

NewsGuest UserJuly 20, 2021Nimium Therapeutics, Paraza, Collaboration

SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche

MONTREAL--(BUSINESS WIRE)--SemaThera Inc. today announced the signing of a multi-year research collaboration and licensing agreement with Roche. The partnership will focus on developing SemaThera’s promising new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.

NewsGuest UserMarch 22, 2021SemaThera, Roche, Collaboration